Application of 1H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis  by Zabek, Adam et al.
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a  b  s  t  r  a  c  t
Rheumatoid  arthritis  is a chronic  autoimmune-based  inﬂammatory  disease  that leads  to progressive
joint  degeneration,  disability,  and  an increased  risk  of cardiovascular  complications,  which  is the  main
cause  of  mortality  in this  population  of  patients.  Although  several  biomarkers  are  routinely  used in the
management  of  rheumatoid  arthritis,  there  is  a high  demand  for  novel  biomarkers  to  further  improve  the
early diagnosis  of  rheumatoid  arthritis,  stratiﬁcation  of patients,  and  the  prediction  of  a better  response
to  a  speciﬁc  therapy.
In  this  study,  the metabolomics  approach  was  used  to  provide  relevant  biomarkers  to improve  diag-
nostic  accuracy,  deﬁne  prognosis  and  predict  and monitor  treatment  efﬁcacy.  The results  indicated  that
twelve metabolites  were  important  for the  discrimination  of  healthy  control  and  rheumatoid  arthritis.
Notably,  valine,  isoleucine,  lactate,  alanine,  creatinine,  GPC  APC and histidine  relative  levels  were  lower in
rheumatoid  arthritis,  whereas  3-hydroxyisobutyrate,  acetate,  NAC,  acetoacetate  and  acetone  relative  lev-
els  were  higher.  Simultaneously,  the  analysis  of  the  concentration  of  metabolites  in rheumatoid  arthritis
and  3  months  after  induction  treatment  revealed  that  L1, 3-hydroxyisobutyrate,  lysine,  L5, acetoacetate,
creatine,  GPC  +  APC, histidine  and phenylalanine  were  elevated  in RA,  whereas  leucine,  acetate,  betaine
and  formate  were  lower.  Additionally,  metabolomics  tools  were  employed  to discriminate  between
patients  with  different  IL-17A  genotypes.
Metabolomics  may  provide  relevant  biomarkers  to  improve  diagnostic  accuracy,  deﬁne  prognosis  and
predict and  monitor  treatment  efﬁcacy  in rheumatoid  arthritis.
© 2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).. IntroductionRheumatoid arthritis (RA) is a chronic autoimmune-based
nﬂammatory disease that leads to progressive joint degeneration,
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ttp://dx.doi.org/10.1016/j.jpba.2015.10.007
731-7085/© 2015 The Authors. Published by Elsevier B.V. This is an open access article udisability, and an increased risk of cardiovascular complications,
which is the main cause of mortality in this population [1]. The
etiopathogenesis of RA is multifactorial and not fully known,
which is characteristic of most autoimmune diseases. An improved
understanding of RA etiopathogenesis and immunological dis-
orders has led to modern therapeutic options, including TNF-
inhibitors. Although therapy with TNF- inhibitors constitutes a
breakthrough in RA management, no improvement is achieved in
approximately 30% of cases, and another 20% of patients discon-
tinue therapy because of side effects. There is also an ongoing
search for biochemical and clinical markers that would allow the
prediction of a good response to therapy with biologicals, includ-
ing TNF- inhibitors. Moreover, the results of our recent studies
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. The PCA model ((A); R2Xcum = 0.437, Q2cum = 0.272) and PLS-DA model ((B);
R2Xcum = 0.551, Q2cum = 0.761) with the ROC curve (C) for comparison of the HC and
RA  groups. Blue circles—healthy controls; yellow boxes—patients before anti-TNF-
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Fig. 2. The PCA model ((A); R2Xcum = 0.513, Q2cum = 0.351) and PLS-DA model ((B);
R2Xcum = 0.475, Q2cum = 0.767) with the ROC curves (C) for comparison of the RA
and RAT groups. Yellow boxes—patients before treatment; red triangles—patients
after 3 months of anti-TNF- treatment. Empty symbols—the prediction set; solidreatment. Empty symbols—the prediction set; solid symbols—the model set. (For
nterpretation references to color in this ﬁgure legend, the reader is referred to the
eb  version of this article.)
ave suggested that genetic variations within genes encoding for
actors involved in inﬂammatory processes associated with RA
evelopment may  play a signiﬁcant role in disease susceptibility,
rogression and response to anti-TNF- treatment [2,3]. In addi-
ion to clinical factors, genetic predisposition in combination with
etabolomics may  be helpful in clinical predictions. Although sev-
ral biomarkers are routinely used in the management of RA, there
s a high demand for novel biomarkers to further improve the early
iagnosis of RA, the stratiﬁcation of patients, and the prediction
f a better response to speciﬁc therapies. In addition to genomics
nd proteomics, the implementation of metabolomic techniques
ay  also improve our knowledge of the etiopathology of RA [4], ashown in our previous work in patients with inﬂammatory bowel
isease [5] and pulmonary disease [6].
The present study assessed the potential impact of the appli-
ation of metabolomic studies in patients with RA to determinesymbols—model set. (For interpretation references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
whether metabolomic biomarkers of disease diagnostics and dis-
ease activity can be identiﬁed.
2. Materials and methods
2.1. Study population/characteristics of RA patients
The study included 20 Caucasian women  patients meeting the
EULAR/ACR (European League Against Rheumatism/American Col-
lege of Rheumatology) 2010 criteria for (RA) and 30 healthy female
volunteers (HC) as the control group. The patient characteristics
are presented in Table 1. There was no statistically signiﬁcant dif-
ference in sex and age between the populations.
Seventy serum samples were collected from adult individuals
(women), including 40 samples obtained from 20 patients before
546 A. Zabek et al. / Journal of Pharmaceutical and B
Table 1
Demographic data and clinical proﬁles of patients included in the study.
Feature Value
RA patients (N=) 20
Age (years) 54 ± 12.3 (range: 28–74)
Females (%) 100
Disease duration (years) 12 ± 8.26 (range 3–25)
Disease onset (years) 42 ± 12.1 (range 17–65)
Current smokers (%) 18
RF+ (%) 80
ACPA+ (%) 85
DAS28 at baseline 6.84 ± 0.63 (range 5.24–8.05)
DAS28 at week 12 of anti-TNF drug 4.22 ± 1.10 (range 2.1–5.31)
Etanercept (%) 80
Adalimumab (%) 20
Glucocorticoids (%) 90 (mean dose 8 mg prednisone daily)
Methotrexate (%) 90 (mean dose 20.6 mg weekly)
RA—rheumatoid arthritis; RF—rheumatoid factor; ACPA—anti-citrullinated protein
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and area under curve (AUC) values. For this purpose, a per-ntibody; DAS28—disease activity score in 28 joints.
nd after 3 months of treatment (RAT) and 30 control serum sam-
les collected from healthy individuals.
The female patients enrolled in the study were ≥18 years of
ge with active, adult-onset RA. The mean disease duration was
2 (range: 3–25) years. All the patients provided written informed
onsent. The study was approved by the Wroclaw Medical Univer-
ity Ethics Committee (No. KB 577/2011, 10.11.2011).
The following inclusion criteria were accepted: consent to par-
icipate in the study; active form of the disease–disease activity
core based on erythrocyte sedimentation rate and an evaluation
f 28 joints (DAS28) ≥5.1; failure of treatment with at least 2 csD-
ARDs; over 18 years of age; women with reproductive potential
ere required to use reliable contraception.
The following exclusion criteria were applied: pregnancy or
reastfeeding; coexistence of other systemic diseases of connective
issue besides RA; clinically signiﬁcant impairment of hepatic and
enal function; alcohol abuse; infection with hepatotropic viruses;
nfections resistant to therapy; ongoing history of cancer if no
ure was achieved; uncontrolled diabetes; and patient unwilling
r unable to cooperate.
The patients were administered the recommended doses of
NF- inhibitors (etanercept [ETA] or adalimumab [ADA]) as fol-
ows: subcutaneous injection of ADA at 40 mg  every other week and
ubcutaneous injection of ETA at 50 mg  every week. The patients
ere allowed to continue treatment with csDMARDs, glucocorti-
oids or non-steroidal anti-inﬂammatory drugs if the treatment
egimens were not modiﬁed for 4 weeks before the study. In total,
0% of patients were treated with a stable dose of methotrexate
mean dose: 20.6 mg  weekly), and 90% patients were treated with
lucocorticoids (mean dose: 8 mg  daily of prednisone). To examine
he response to anti-TNF therapy in RA, blood samples, laboratory
ata, and clinical data were collected at baseline (prior to anti-TNF
herapy) and at 3 months after treatment. The clinical evaluation
as based on medical history, number of painful and swollen joints,
ain intensity assessed by the patient on a 100-mm visual ana-
ogue scale (VAS) and laboratory tests (erythrocyte sedimentation
ate [ESR], C-reactive protein [CRP]), blood cell count, aspartate
minotransferase (AST) activity, alanine aminotransferase (ALT)
ctivity, serum creatinine, urea levels and urinalysis. The param-
ters allowed for the determination of improvement according to
he criteria based on DAS28 as suggested by the EULAR. According
o the EULAR deﬁnition, the patients were classiﬁed as good, mod-
rate, or non-responders, using the individual amount of change
n the DAS28 (DAS28) and DAS28 values at 3. Moreover, in some
nalyses, a comparison was made between non-responders versus
atients in remission or low disease activity according to the EULARiomedical Analysis 117 (2016) 544–550
response criteria. This stratiﬁcation was due to the limited number
of patients in each group.
2.2. IL-17A genotyping
The biallelic polymorphism within the IL-17A gene (rs2275913;
G-197A) was  studied as previously described by Bogunia-Kubik
et al. [2]. In brief, DNA was  extracted from peripheral blood taken on
EDTA using the Maxwell 16 Blood DNA Puriﬁcation Kit (Promega
Corp., Madison, WI,  USA) following the recommendations of the
manufacturer. The IL-17A (rs2275913; G-197A) alleles were deter-
mined by real-time polymerase chain reaction (PCR) ampliﬁcations
with the use of the LightSNiP assay designed by TIB MOLBIOL
(GmbH, Berlin, Germany). The reaction was performed following
the recommendation of the manufacturer, and the typing results
were analyzed using a Roche LightCycler 480 instrument.
2.3. Sample preparation for proton NMR spectroscopy
Serum was  sampled from the peripheral vein and centrifuged
for 10 min  at 4000 × g. The samples were frozen in liquid nitrogen
immediately after collecting and stored at −80 ◦C until analysis.
Prior to the metabolomic experiment, the serum samples were
thawed at room temperature and vortexed. Next, the mixtures of
200 L of serum and 400 L of saline solution (prepared from 0.9%
NaCl, 15% D2O and 3 mM TSP) were mixed again. After centrifu-
gation (12 000 × g, 10 min), an aliquot of 550 L of each sample
supernatant was subsequently transferred to a 5 mm NMR  tube.
The samples were kept at 4 ◦C before measurement.
2.4. 1H NMR  measurements
The NMR  spectra of serum samples were recorded at 300 K using
an Avance II spectrometer (Bruker, GmBH, Germany) operating at
a proton frequency of 600.58 MHz. The NMR  spectra of the serum
samples were recorded using a CPMG pulse sequence with water
presaturation in the Bruker notation. For each sample, 128 scans
were collected with a spin-echo delay of 400 s; 80 loops; relax-
ation delay of 3.5 s; acquisition time of 2.73 s; TD of 64 k; and SW
of 20.01 ppm.
Spectra were processed with a line broadening of 0.3 Hz and
manually phased and baseline corrected using Topspin 1.3 soft-
ware (Bruker, GmBH, Germany) and referenced to the -glucose
signal ı = 5.225 ppm. The correction of peak positions (alignment)
was performed using the correlation optimized warping algorithm
COW and the icoshift algorithm implemented in Matlab (Matlab
v. 8.1, Mathworks Inc.) [7,8]. The spectra-consistent 47 599 data
points were normalized using the Probabilistic Quotient Normal-
ization (PQN) method [9].
2.5. Multivariate data analysis for biomarker identiﬁcation
Prior to chemometrics analysis, the data set was  Pareto scaled.
For primary visualization, distribution and clustering, the PCA
model was  applied. Next, the discriminant version of the Partial
Least Squares regression (PLS-DA) with a 7-fold cross validation
procedure (CV, 1/7 of the samples being excluded from calcula-
tions in each round) to determine variation between data sets was
adopted.
The prediction performance of the PLS-DA models was  esti-
mated based on receiver operating characteristic (ROC) curvesfcurve function from the Matlab statistical tool-box (Matlab v.
8.1, Mathworks, Inc.) was adopted. Speciﬁcity and sensitivity were
determined according to sample class prediction using the 7-fold
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wig. 3. The PCA model ((A); R2Xcum = 0.731, Q2cum = 0.537) and PLS-DA model ((B); 
ontrol; red tringles—patients after 3 months treatment. (For interpretation referen
ross-validated predicted values of the ﬁtted Y-predcv (imple-
ented in SIMCA-P+ software) for observations in the model.
.6. Statistical data analysis
The concentration of the metabolites based on 1H NMR
pectroscopy was calculated as relative signal integrals of the
on-overlapping resonances (or a cluster of partly overlapping
esonances). The metabolite resonances were identiﬁed accord-
ng to assignments published in the literature and in on-line
atabases (Biological Magnetic Resonance Data Bank and Human
etabolome Data Base). For each metabolite, the percentage dif-
erence (PD) and relative standard deviation (RSD) were calculated
sing STATISTICA 10. The percentage difference was  calculated
ased on the average values of relative signal integrals in each
roup. For each metabolite, the statistical signiﬁcance based on
tudent’s t test was calculated (p value less than 0.05).
.7. Metabolite pathway analysis
To identify the most altered metabolic pathways, a set of signif-
cantly altered metabolites was used as the input for Metabolite
athway Analysis (MetPA). The MetPA analysis was performed
ith a free on-line tool (http://www.msea.ca). Over-representation
nalysis (ORA) was used for comprehensive screening of affected
athways. P-values and false discovery rates (FDR) are reported
10].
. Results
.1. Response to treatmentClinical data from 20 female Caucasian patients with RA treated
ith TNF- inhibitors were analyzed. Among them, 80% were
reated with ETA and 20% with ADA (Table 1). The mean DAS28 at
he onset of biologic treatment was 6.84 ± 0.63 (range 5.24–8.05).
ig. 4. The PCA model ((A); R2Xcum = 0.554, Q2cum = 0.307) and PLS-DA model ((B); R2Xcum
reen  diamonds—GG homozygosis; black inverted triangles—AA and GA genotypes. (For 
eb  version of this article.)= 0.528, Q2cum = 0.946) for comparison HC and RAT group. Blue circles—healthy
 color in this ﬁgure legend, the reader is referred to the web version of this article.)
No difference in DAS28 values (ETA—6.51 ± 0.66, ADA—6.54 ± 0.63,
p = 0.1390) was detected between subgroups treated with differ-
ent TNF- inhibitors. The mean DAS28 after 24 weeks of treatment
was 4.22 ± 1.10 (range 2.1–5.31). A moderate EULAR response was
achieved in 55% of patients, while a good EULAR response was
achieved in 20% of patients at 3 months.
3.2. Clustering of tested samples
The 1H NMR-based metabolomics study was  performed on 20
patients with rheumatoid arthritis: before and 3 months after
induction of therapy with anti-TNF-  agents, and 30 healthy
controls. The representative median spectrum of serum samples
obtained from RA with assigned metabolites is shown in Fig. 1S.
To visualize the clustering of tested samples, a PCA model was
constructed. The two ﬁrst principal components (PCs) showed a
distinct separation between the following groups (Fig. 2S(A)). Gen-
erally, the PC1 explained 25.5% of the total variance, and the PC2
explained 14.9%. Better classiﬁcation and clear separation could
be observed in the PLS-DA model (Fig. 2S(B)) with good model
parameters (R2Xcum = 0.635, Q2cum = 0.845) and statistically signif-
icant values by CV-ANOVA (less than 0.05).
3.3. Metabolomic basis of rheumatoid arthritis
Using the serum samples, the metabolic basis of rheumatoid
arthritis was studied. For this purpose, groups of HC and RA were
compared. The sample separation based on the PCA model is shown
in Fig. 1(A).
The potential biomarkers were found using the PLS-DA model
(Fig. 1(B)). The results showed that twelve metabolites were impor-
tant for the discrimination of the groups HC and RA (Table 2). Note
that valine, isoleucine, lactate, alanine, creatinine, GPC + APC and
histidine were lower in RA, while 3-hydroxyisobutyrate, acetate,
NAC, acetoacetate and acetone were higher.
The predictive ability and validation of the PLS-DA
model were determined using the predictive set of samples.
= 0.534, Q2cum = 0.627) for comparison of patients with polymorphisms of IL-17A.
interpretation references to color in this ﬁgure legend, the reader is referred to the
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Table 2
The changes in relative integrals of serum metabolites.
Metabolite Percentage difference Relative standard deviation [%]
RA vs. HC RAT vs. HC HCHCRAT RA vs. RAT HC RA RAT
L1 −7.5 −25.6a 18.1a 15.0 13.3 18.9
L2  7.5 5.7 1.8 28.8 24.8 23.8
Leucine −4.3 11.9a −16.2a 12.3 14.6 9.7
Valine −17.2a −7.1 −10.1 17.3 24.2 12.4
Isoleucine −11.7a −14.2a 2.5 14.4 18.8 9.4
3-Hydroxyisobutyrate 18.3a −2.9 21.2a 23.9 32.7 18.4
L3  −2.6 −16.2a 13.5 27.0 25.5 24.4
Lactate −26.5a −15.0 −11.6 29.8 23.5 23.0
Alanine −24.3a −19.6a −4.7 17.7 18.0 14.4
L4  2.0 −12.3 14.3 39.5 35.0 30.4
Lysine −0.3 −7.8a 7.5a 11.1 12.2 9.1
Acetate 47.2a 67.6a −22.1a 30.1 22.6 20.6
L5  1.4 −8.5a 9.9a 14.4 13.8 14.0
NAC  15.3a 16.8a −1.5 9.9 11.1 11.2
Acetoacetate 55.1a 29.7a 26.5a 33.5 44.2 30.6
Acetone 17.4a 15.4a 2.0 11.5 23.0 9.8
Unk  1 −32.8 −46.7a 14.5 30.7 30.6 9.2
Citrate 4.0 9.6a −5.6 11.1 10.9 6.6
Creatine −3.0 −15.3a 12.3a 18.2 16.8 16.6
Creatinine −11.5a −17.6a 6.1 14.1 18.4 11.0
Choline −1.4 5.8 −7.2 29.8 18.2 25.1
GPC  + APC −11.6a −21.8a 10.3a 12.0 14.6 16.7
Betaine −13.5 5.5 −19.0a 28.6 25.9 24.2
Glucose 6.7 2.3 4.4 12.4 11.6 9.3
L6  −1.8 −13.4 11.6 24.2 19.0 21.7
Tyrosine −8.8 −34.5a 25.9 27.5 55.1 21.9
Histidine −36.4a −49.6a 13.9a 14.7 16.7 20.7
Phenylalanine 3.4 −48.7a 52.0a 16.6 42.5 26.2
Formate 60.7 138.7a −98.8a 58.8 122.6 12.8
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aercentage difference was  calculated based on the average values of relative signal
a Statistically signiﬁcant metabolites based on Student’s t test.
ccording to the ROC curve (Fig. 1(C)) and the AUC values
model set = 0.893; prediction set = 1.000), the PLS-DA model
howed excellent discriminant properties for comparing HC and
A (Fig. 3S).
.4. Metabolomic monitoring of the rheumatoid arthritis
reatment
In this study, the metabolomic serum approach was also
mployed for monitoring the rheumatoid arthritis treatment. For
his purpose, the RA and RAT groups were compared.
The PCA model (Fig. 2(A)) showed a clear separation between
A and RAT according to the two ﬁrst PCs. PC1 represented 27.1%
f total variance, whereas PC2 represented 14.8%. For selection of
he most important metabolites allowing the separation of RA and
AT, the PLS-DA model was constructed (Fig. 2(B)). Simultaneously,
he ROC curve (Fig. 2(C)) and AUC values (model set = 0.964; pre-
iction set = 1.000) showed excellent predictive properties for this
omparison (Fig. 3S). The analysis of the relative concentration of
etabolites revealed that L1, 3-hydroxyisobutyrate, lysine, L5, ace-
oacetate, creatine, GPC + APC, histidine and phenylalanine were
levated in RA, while leucine, acetate, betaine and formate were
ecreased.
When the HC group was compared to RAT both the PCA and
LS-DA models showed that patients after treatment did not move
oward the healthy controls but rather formed a separate group
Fig. 3(A) and (B)) (Fig. 3S).
.5. Metabolic changes related to the IL-17A polymorphism in
atients with RAIn our previous study, the IL-17A (rs2275913, G-197A) poly-
orphism was found to affect RA progression and response to
nti-TNF-  treatment. Interestingly, the separation of patientsals in each group. The calculations were made from left to right.
according to the IL-17A polymorphism (GG vs. GA, AA genotype
carriers) can also be observed from the PCA and PLS-DA models
(Fig. 4(A) and (B)). However, the number of tested samples should
be higher for validation of this observation (Fig. 3S).
4. Discussion
4.1. Metabolic basis of RA
Rheumatoid arthritis is one of the most common autoimmune
diseases, especially frequent among females, and causes systemic
inﬂammation associated with joint lesions, leading to an uncom-
fortable life style for patients. In this study, we demonstrated
the global metabolome obtained using 1H NMR  spectroscopy and
showed the primary changes in metabolite proﬁle related to RA.
The metabolite pathway analysis based on MetPA as well as
the KEGG PATHWAY database (http://www.genome.jp/kegg/) indi-
cated that the main differences between HC and RA are related to
the network of propanoate metabolism; the synthesis and degra-
dation of ketone bodies; valine, leucine and isoleucine degradation;
glycolysis or gluconeogenesis; pyruvate metabolism; and glyc-
erophospholipid metabolism (Fig. 4S). Yang et al. and Lauridsen
et al. suggested that an elevated level of lactate could be one of the
main biomarkers for the diagnosis of chronic inﬂammatory enti-
ties [11–13]. Indeed, lactate as a product of pyruvate is reported
to be associated with a pathogenic role [11–13]. Moreover, the
higher lactate relative concentration in RA may  be related to low
oxygen levels prevalent in inﬂammatory environments (increased
NAC—N-acetylated glycoprotein) and the induction of hypoxia,
promoting anaerobic respiration [11–16]. In opposite to above
mentioned result we observed a reduced relative level of lactate
among RA patients in comparison to HC subjects. The MetPA anal-
ysis (Fig. 4S) showed that a decreased relative concentration of
lactate might be correlated with an increased overproduction of
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etone bodies, acetate, acetoacetate and acetone. Moreover, in this
tudy, we observed in RA patients the degradation of ketogenic
mino acids, valine and isoleucine and a higher relative level of
-hydroxyisobutyrate (keto-metabolite).
Biosynthesis of the ketone bodies appears to be signiﬁcantly
ombined with a limited energy source caused by low oxygen
onditions in pathogenically changed tissues. However, inspec-
ion of Table 2 shows that the TCA cycle is intact; hence, energy
emand should be assured by glucose utilization. The excess of
etone bodies in comparison to HC might reveal an inability in
isposing ketone bodies or their overproduction by accelerated bio-
hemical pathways. This ﬁnding might be a characteristic feature
or RA patients. The decreased relative level of creatinine in both
tages of RA and RAT, and only creatine in RAT, may  suggest a lack
f rapid conversion of creatine to creatinine during the progres-
ion of the disease, while after treatment, the relative levels of
oth metabolites are lower. The reduced relative level of deriva-
ives of choline, namely, sn-glycero-3-phosphocholine (GPC) and
cetylphosphocholine (APC), may  indicate an extensive turnover
f cell membranes (simultaneous degradation and biosynthesis)
nder inﬂammatory conditions [17].
.2. Biomarkers for treatment efﬁcacy
In this study, the metabolomics approach was used for assess-
ent of the TNF- inhibitor treatment. For this purpose, patients
efore and after three months of treatment were compared. We
bserved that the global metabolome measured by 1H NMR  spec-
roscopy was changed. Simultaneously, the potential biomarkers
f efﬁcacy of treatment were selected. Thirteen metabolites were
tatistically signiﬁcant and determined the separation of the RA
nd RAT patients. The general overview of this set of metabo-
ites showed that despite well-being during treatment, the patients
re still far removed from the homeostasis represented by HC.
owever, there was no overlap with rheumatoid arthritis and
nﬂammation in the global metabolome. There was a reduced rel-
tive level of ketone bodies, such as 3-hydroxyisobutyrate and
cetoacetate, and an increased relative level of one ketogenic amino
cid (leucine). Acetate was considerably higher after treatment. The
ersistent inﬂammatory process could be conﬁrmed by the reduced
elative level of LDL as a result of the activity of secretory phospho-
ipase A2 that promotes the hydrolysis of phospholipids in LDL and
LDL. On the other hand, phenylalanine was decreased; thus, the
mmune system and inﬂammatory processes were not activated by
he impairment of phenylalanine-4-hydroxylase [18]. The reduced
elative level of GPC and APC, as well as the elevated concentration
f betaine, indicate the turnover of phospholipids associated with
eorganization of cell membranes. Finally, formate was  increased
formed in the colonic lumen by intestinal bacteria, e.g., Enterobac-
eriaceae, in the process of unabsorbed carbohydrate fermentation)
nd may  be related to rearrangement in the gut microbiome [19].
The comparison of RAT patients to HC subjects revealed that
fter treatment with TNF- inhibitors, the RAT patients still showed
igns of RA in the global metabolome. Thus, the question arises as
o whether this treatment can restore one to health or if it merely
emporarily disables the disease. Similar results were found by Lau-
idsen et al., where RA active group after treatment was  almost of
he same metabolic signature as group with RA in remission but
till both group were different than HC [13]. However, the direc-
ion of changes in metabolites level as well the biomarker pool do
ot coincide with all our results.
.3. Metabolic relationships with polymorphic variants of the
L-17A gene
There are no reports of the results of metabolomic and genomic
tudies in patients with RA. In this study, metabolomics tools wereiomedical Analysis 117 (2016) 544–550 549
employed to discriminate patients with different IL-17A genotypes.
Interestingly, both PCA and PLS-DA models showed signiﬁcant dif-
ferences between patients carrying the GG and AG/AA genotypes.
These results are even more interesting because in our previous
study we found that the GG homozygosity was associated with
unfavorable outcome in female patients with RA. These patients
more frequently presented with stage 4 RA and were character-
ized by more active disease after 3 months of therapy with TNF
inhibitors [20]. Obviously due to a relatively small number of cases
analyzed, more extended studies are required to validate our obser-
vations on the effect of genetic and metabolomic results and their
prognostic value for females with RA. Nevertheless, these data con-
cur with the previous observations, and suggest that the results of
metabolomic (similarly to genetic) studies are of prognostic value
for patients with RA.
5. Conclusion
Metabolomics may provide relevant biomarkers to improve
diagnostic accuracy, deﬁne prognosis and predict and monitor
treatment efﬁcacy in RA.
Future advances of metabolomics in biomedical research will
be particularly useful in the domain of rheumatic diseases, both for
the identiﬁcation of biomarkers and for new therapeutic targets.
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